PMV Pharmaceuticals (NASDAQ:PMVP) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP) in a research note released on Tuesday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.33) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.27) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.38) EPS and FY2025 earnings at ($1.47) EPS.

Several other research firms also recently weighed in on PMVP. Craig Hallum assumed coverage on shares of PMV Pharmaceuticals in a research note on Monday, May 13th. They issued a buy rating and a $6.00 target price for the company. Jefferies Financial Group began coverage on PMV Pharmaceuticals in a research note on Friday, April 12th. They issued a buy rating and a $5.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $5.75.

PMV Pharmaceuticals Trading Down 2.3 %

PMVP opened at $2.10 on Tuesday. PMV Pharmaceuticals has a twelve month low of $1.17 and a twelve month high of $9.72. The company’s 50-day moving average price is $1.78 and its two-hundred day moving average price is $2.01.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.08. Sell-side analysts expect that PMV Pharmaceuticals will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On PMV Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in PMVP. Acadian Asset Management LLC raised its holdings in shares of PMV Pharmaceuticals by 170.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company’s stock valued at $3,533,000 after acquiring an additional 1,311,745 shares in the last quarter. BML Capital Management LLC purchased a new stake in PMV Pharmaceuticals in the first quarter valued at approximately $2,221,000. Alkeon Capital Management LLC lifted its position in PMV Pharmaceuticals by 58.6% during the third quarter. Alkeon Capital Management LLC now owns 2,347,414 shares of the company’s stock valued at $14,413,000 after purchasing an additional 867,547 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in PMV Pharmaceuticals by 92.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 826,704 shares of the company’s stock worth $1,405,000 after buying an additional 397,062 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in shares of PMV Pharmaceuticals by 125.8% in the 4th quarter. Vontobel Holding Ltd. now owns 685,985 shares of the company’s stock worth $2,127,000 after buying an additional 382,161 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.